At the close on Monday, shares in Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc. rose 2.16%, ending the day at $16.08. The stock recorded a trading volume of 914,346 shares. The Company's shares have advanced 6.49% in the previous three months and 38.74% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.75% and 21.84%, respectively. Moreover, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 58.79.
On December 19th, 2016, Ironwood Pharmaceuticals announced that its partner, Astellas Pharma Inc., secured marketing approval from the Japanese Ministry of Health, Labor, and Welfare for LINZESS as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) in Japan. Ironwood anticipates that Astellas will launch the drug in H1 2017. Linaclotide is a guanylate cyclase-C (GC-C) receptor agonist currently approved and available for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) in the US and more than 30 other countries. Access our complete research report on IRWD for free at:
Shares in Parsippany, New Jersey-based The Medicines Co. ended the day 1.74% lower at $36.13 with a total trading volume of 682,446 shares. The stock is trading above its 50-day and 200-day moving averages by 2.11% and 0.93%, respectively. Shares of the Company, which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 52.05.
On November 15th, 2016, Medicines Co. and Alnylam Pharmaceuticals, Inc. announced positive results from the analysis of Day 90 data for 497 patients, as well as analysis of preliminary Day 180 data for 189 patients, enrolled in the ORION-1 Phase 2 study of inclisiran. Inclisiran is an investigational GalNAc-conjugated RNAi therapeutic targeting PCSK9- a genetically validated protein regulator of LDL receptor metabolism-being developed for the treatment of hypercholesterolemia. Inclisiran was generally well tolerated and no material safety issue was observed, including no elevations of liver enzymes considered related to study medication and no neuropathy or change in renal function.
On December 05th, 2016, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, issuing a target price of $57 per share. The complimentary research report on MDCO can be downloaded at:
On Monday, shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. finished 1.68% higher at $24.20 with a total trading volume of 850,865 shares. The stock has advanced 7.56% in the last one month. The Company's shares are trading above their 50-day moving average by 6.41%. Additionally, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 54.54.
On November 30th, 2016, Lannett announced that the US FDA granted the Company a 90-day extension to submit documentation concerning its Methylphenidate Hydrochloride Extended-Release Tablets. The new deadline for submitting the supporting documentation is March 20, 2017. The Company is hopeful that the extension will allow the Agency sufficient time to provide the underlying documents on which its decision was based. Register for free on Stock-Callers.com and get access to the latest PDF format report on LCI at:
Jersey City, New Jersey headquartered SCYNEXIS Inc.'s shares recorded a trading volume of 311,252 shares at the end of yesterday's session. The stock closed the day 3.38% higher at $3.36. The Company's shares are trading above their 200-day moving average by 0.17%. Additionally, shares of SCYNEXIS, which develops and commercializes novel anti-infectives to address unmet therapeutic needs, have an RSI of 41.08.
On December 13th, 2016, SCYNEXIS announced two new development milestones for SCY-078, a novel antifungal agent. The SCY-078 Phase 1 intravenous (IV) Program consists of single-ascending and multiple-ascending dose studies to test different IV formulations and doses in healthy volunteers followed by oral regimens. Based on the available safety and pharmacokinetics data from this program, the Company has identified an IV formulation and dose regimen that, pending discussions with the FDA, will be tested in the upcoming clinical trials of SCY-078. Additionally, the SCY-078 toxicology program was expanded to include three-month oral dose studies in two species (rats and dogs). Download your free research report on SCYX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA